Stock listing

OTC:MYRX Myrexis Inc Stock

Follow Myrexis Inc into a list and get an email when it puts out news.

Share price · OTC:MYRX

$0.0008 USD 0.0000 (0.0%)

Close on Nov 19, 2026

Past year +166.7% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.0008 – $0.0008 USDNov 19, 2026
Market cap
$27,583 USDAt the close on Nov 19, 2026 · price × 34.48M shares outstanding
52-week range
$0.0003 – $0.0050 USDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$1 USDMedian day 0 shares · 61 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Myrexis Inc logo

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · OTC:MYRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00082,175
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.0008500
$0.00080.00000.0%$0.0008$0.0008$0.0008100
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.0008200
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0050$0.0050$0.000850,000
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.0008512
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
Ticker
OTC:MYRX
Asset type
Stock
Exchange
OTC
Currency
USD

Valuation

price Nov 19, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
0.03

Team and board

OfficerRole
Jonathan CouchmanChief Executive Officer and Chief Financial Officer

Events

QuarterResultsShare move
Quarter to Dec 31, 2024Feb 7, 2025+14.3%
Quarter to Sep 30, 2024Nov 18, 2024−1.4%
Quarter to Jun 30, 2024Sep 6, 20240.0%
Quarter to Mar 31, 2024May 10, 20240.0%
Quarter to Dec 31, 2023Feb 9, 2024+13.6%
Quarter to Sep 30, 2023Nov 9, 20230.0%
Quarter to Jun 30, 2023Sep 8, 20230.0%
Quarter to Mar 31, 2023May 12, 20230.0%
Quarter to Dec 31, 2022Feb 10, 2023
Quarter to Sep 30, 2022Nov 10, 2022
All 17 quarters
QuarterResultsShare move
Quarter to Jun 30, 2022Sep 9, 2022
Quarter to Mar 31, 2022May 13, 2022
Quarter to Dec 31, 2021Feb 11, 2022
Quarter to Sep 30, 2021Nov 11, 20210.0%
Quarter to Jun 30, 2021Sep 10, 2021−1.8%
Quarter to Mar 31, 2021May 7, 20210.0%
Quarter to Dec 31, 2020Feb 12, 2021+6.7%

Open Events

Financials

Annual, in USD

Income statement

LineFY2013FY2012FY2011FY2010FY2009FY2008
Revenue00185.0K90.0K5.46M110.8M
Cost of revenue00712.0K1.15M53.7M118.9M
Gross profit00185.0K90.0K5.46M110.8M
Research and development465.0K14.2M22.3M28.2M54.6M121.5M
Selling, general and administrative10.7M17.6M17.2M21.1M
Operating income-12.0M-31.8M-39.4M-48.1M-58.1M-31.4M
Depreciation and amortization387.0K1.28M1.66M1.35M2.85M3.21M
EBITDA-11.6M-30.5M-37.7M-46.8M-55.3M-28.1M
Interest expense000000
Income before tax-11.6M-31.2M-38.7M-47.0M-34.4M
Income tax-370.0K-592.0K-2.30M-1.17M3.02M
Net income-11.6M-31.2M-38.7M-47.0M-58.1M-34.4M
Earnings per share, basic-0.39-1.18-1.52-1.91-2.42-1.43

Balance sheet

LineFY2013FY2012FY2011FY2010FY2009FY2008
Cash and equivalents1.14M19.7M19.2M35.9M128.4M
Short-term investments75.0K68.7M86.4M103.0M40.7M
Receivables4.55M
Current assets1.24M89.5M107.5M139.3M169.3M5.18M
Property, plant and equipment649.0K3.31M6.00M5.34M10.3M
Total assets1.24M91.7M121.3M154.1M193.7M15.7M
Accounts payable74.0K197.0K197.0K1.21M14.2M
Current liabilities74.0K2.28M3.31M4.25M4.58M46.6M
Total liabilities74.0K2.28M3.31M4.25M4.58M46.6M
Shareholders' equity1.16M89.4M118.0M149.9M189.1M-30.8M
Shares outstanding29.9M26.4M25.5M24.5M24.0M24.0M

Cash flow

LineFY2013FY2012FY2011FY2010FY2009FY2008
Cash from operations-13.0M-27.8M-33.5M-40.4M-60.7M12.2M
Capital spending0-55.0K-93.0K-2.13M-375.0K-2.33M
Free cash flow-13.0M-27.8M-33.5M-42.5M-60.7M12.2M
Cash from investing71.3M27.1M14.8M-54.4M-7.38M-2.55M
Cash from financing-76.9M1.17M1.95M2.35M196.4M-9.63M
Dividends paid-78.6M
Share buybacks1.63M1.17M1.95M2.34M
Change in cash-18.6M518.0K-16.7M-92.5M128.4M

Open Financials

Cap table

Built by 6ix from Myrexis Inc’s releases

Common shares
34,479,051
Fully diluted
34,479,051

Fully diluted

LineShares
Common shares34,479,051

Share count over time

CountShares
Nov 22, 202634,479,051

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
The Gabelli ABC Fund433K1.3%US$346Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jason M. Aryeh
Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Orchestra BioMed Holdings, Inc. (Director · Since at least Jan 26, 2023); Anebulo Pharmaceuticals, Inc. (Board Member · Since at least May 6, 2021); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past)
Director · Oct 19, 2011 – Jun 18, 2012 · Past
Dennis Langer
Other companies: Quoin Pharmaceuticals. Ltd (Director · Since at least Jan 1, 2023); Ernexa Therapeutics Inc. (Director · May 1, 2021 – Dec 8, 2021 · Past); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past)
Director · Dec 8, 2011 – Dec 8, 2011 · Past
Michael C. Pearce
Other companies: Journey Medical Corporation (Director · Since at least Jul 9, 2024); Enveric Biosciences, Inc. (Director · May 9, 2008 – May 9, 2008 · Past); Pernix Therapeutics Holdings Inc (President and CEO, Director · Sep 17, 2007 – May 10, 2013 · Past)
Director · Feb 13, 2013 – Feb 13, 2013 · Past
Robert Forrester
Other companies: Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Verastem, Inc. (President and CEO, Director · Jan 26, 2012 – Jan 3, 2019 · Past); EPIRUS Biopharmaceuticals Inc (EVP and COO, Director · May 14, 2007 – Dec 21, 2009 · Past)
Director · Nov 11, 2010 – Dec 8, 2011 · Past
Timothy R Franson
Other companies: Paratek Pharmaceuticals Inc (Director · Jul 21, 2015 – Sep 21, 2023 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 22, 2023 · Past)
Director · Nov 11, 2010 – Dec 8, 2011 · Past
Jonathan Couchman
Other companies: Enzo Biochem Inc (Director · Nov 22, 2024 – Jan 16, 2025 · Past)
Chairman, President and CEO, Director · Jan 22, 2013 – Jan 22, 2013 · Past
W Wayne Laslie
Other companies: Myriad Genetics, Inc. (Chief Operating Officer, MPI · Feb 16, 2006 – May 8, 2009 · Past)
Chief Operating Officer · Sep 24, 2010 – Sep 24, 2010 · Past
Andrew GibbsVP, General Counsel · Sep 24, 2010 – Sep 24, 2010 · Past

Open People

Log in to ask 6ix AI your own questions about Myrexis Inc.